224 related articles for article (PubMed ID: 15215126)
41. Augmented hepatic interferon gamma expression and T-cell influx characterize acute hepatitis progressing to recovery and residual lifelong virus persistence in experimental adult woodchuck hepatitis virus infection.
Hodgson PD; Michalak TI
Hepatology; 2001 Nov; 34(5):1049-59. PubMed ID: 11679978
[TBL] [Abstract][Full Text] [Related]
42. Toll-Like Receptor 8 Agonist GS-9688 Induces Sustained Efficacy in the Woodchuck Model of Chronic Hepatitis B.
Daffis S; Balsitis S; Chamberlain J; Zheng J; Santos R; Rowe W; Ramakrishnan D; Pattabiraman D; Spurlock S; Chu R; Kang D; Mish M; Ramirez R; Li L; Li B; Ma S; Hung M; Voitenleitner C; Yon C; Suresh M; Menne S; Cote P; Delaney WE; Mackman R; Fletcher SP
Hepatology; 2021 Jan; 73(1):53-67. PubMed ID: 32246499
[TBL] [Abstract][Full Text] [Related]
43. Chemoimmunotherapy of chronic hepatitis B virus infection in the woodchuck model overcomes immunologic tolerance and restores T-cell responses to pre-S and S regions of the viral envelope protein.
Menne S; Tennant BC; Gerin JL; Cote PJ
J Virol; 2007 Oct; 81(19):10614-24. PubMed ID: 17652398
[TBL] [Abstract][Full Text] [Related]
44. Efficiency of oxetanocin-G, a novel nucleoside against the woodchuck hepatitis virus.
Ikeda N; Kaneko S; Shimoda A; Inagaki Y; Unoura M; Okada M; Yonekawa Y; Takahashi K; Kobayashi K
J Antimicrob Chemother; 1994 Jan; 33(1):83-9. PubMed ID: 8157578
[TBL] [Abstract][Full Text] [Related]
45. Entecavir, FTC, L-FMAU, LdT and others.
Buti M; Esteban R
J Hepatol; 2003; 39 Suppl 1():S139-42. PubMed ID: 14708692
[TBL] [Abstract][Full Text] [Related]
46. Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection.
Genovesi EV; Lamb L; Medina I; Taylor D; Seifer M; Innaimo S; Colonno RJ; Standring DN; Clark JM
Antimicrob Agents Chemother; 1998 Dec; 42(12):3209-17. PubMed ID: 9835516
[TBL] [Abstract][Full Text] [Related]
47. Intrahepatic Transcriptional Signature Associated with Response to Interferon-α Treatment in the Woodchuck Model of Chronic Hepatitis B.
Fletcher SP; Chin DJ; Gruenbaum L; Bitter H; Rasmussen E; Ravindran P; Swinney DC; Birzele F; Schmucki R; Lorenz SH; Kopetzki E; Carter J; Triyatni M; Thampi LM; Yang J; AlDeghaither D; Murreddu MG; Cote P; Menne S
PLoS Pathog; 2015 Sep; 11(9):e1005103. PubMed ID: 26352406
[TBL] [Abstract][Full Text] [Related]
48. Expression of a new woodchuck IFN-alpha gene by a helper-dependent adenoviral vector in woodchuck hepatitis virus-infected primary hepatocytes.
Salucci V; Lu M; Aurisicchio L; La Monica N; Roggendorf M; Palombo F
J Interferon Cytokine Res; 2002 Oct; 22(10):1027-34. PubMed ID: 12433282
[TBL] [Abstract][Full Text] [Related]
49. Immunosuppression reactivates viral replication long after resolution of woodchuck hepatitis virus infection.
Menne S; Cote PJ; Butler SD; Toshkov IA; Gerin JL; Tennant BC
Hepatology; 2007 Mar; 45(3):614-22. PubMed ID: 17326155
[TBL] [Abstract][Full Text] [Related]
50. Liver-targeted antiviral nucleosides: enhanced antiviral activity of phosphatidyl-dideoxyguanosine versus dideoxyguanosine in woodchuck hepatitis virus infection in vivo.
Korba BA; Xie H; Wright KN; Hornbuckle WE; Gerin JL; Tennant BC; Hostetler KY
Hepatology; 1996 May; 23(5):958-63. PubMed ID: 8621175
[TBL] [Abstract][Full Text] [Related]
51. Adoptive transfer of immunity: a new strategy to interfere with severe hepatitis virus reinfection after woodchuck liver transplantation.
Dahmen U; Dirsch O; Li J; Fiedle M; Lu M; Rispeter K; Picucci M; Broelsch CE; Roggendorf M
Transplantation; 2004 Apr; 77(7):965-72. PubMed ID: 15087755
[TBL] [Abstract][Full Text] [Related]
52. Viral pharmacodynamic model for (-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine (emtricitabine) in chronically infected woodchucks.
Hurwitz SJ; Tennant BC; Korba BE; Liberman I; Gerin JL; Schinazi RF
Antivir Chem Chemother; 2002 May; 13(3):165-76. PubMed ID: 12448689
[TBL] [Abstract][Full Text] [Related]
53. Innate and adaptive immunity associated with resolution of acute woodchuck hepatitis virus infection in adult woodchucks.
Suresh M; Czerwinski S; Murreddu MG; Kallakury BV; Ramesh A; Gudima SO; Menne S
PLoS Pathog; 2019 Dec; 15(12):e1008248. PubMed ID: 31869393
[TBL] [Abstract][Full Text] [Related]
54. Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine.
Zhou T; Saputelli J; Aldrich CE; Deslauriers M; Condreay LD; Mason WS
Antimicrob Agents Chemother; 1999 Aug; 43(8):1947-54. PubMed ID: 10428918
[TBL] [Abstract][Full Text] [Related]
55. Immunization of woodchucks with plasmids expressing woodchuck hepatitis virus (WHV) core antigen and surface antigen suppresses WHV infection.
Lu M; Hilken G; Kruppenbacher J; Kemper T; Schirmbeck R; Reimann J; Roggendorf M
J Virol; 1999 Jan; 73(1):281-9. PubMed ID: 9847331
[TBL] [Abstract][Full Text] [Related]
56. Combination therapy including CpG oligodeoxynucleotides and entecavir induces early viral response and enhanced inhibition of viral replication in a woodchuck model of chronic hepadnaviral infection.
Meng Z; Zhang X; Pei R; Zhang E; Kemper T; Vollmer J; Davis HL; Glebe D; Gerlich W; Roggendorf M; Lu M
Antiviral Res; 2016 Jan; 125():14-24. PubMed ID: 26585244
[TBL] [Abstract][Full Text] [Related]
57. Infection Patterns Induced in Naive Adult Woodchucks by Virions of Woodchuck Hepatitis Virus Collected during either the Acute or Chronic Phase of Infection.
Freitas N; Lukash T; Rodrigues L; Litwin S; Kallakury BV; Menne S; Gudima SO
J Virol; 2015 Sep; 89(17):8749-63. PubMed ID: 26063428
[TBL] [Abstract][Full Text] [Related]
58. Persistence of isolated antibodies to woodchuck hepatitis virus core antigen is indicative of occult infection.
Coffin CS; Pham TN; Mulrooney PM; Churchill ND; Michalak TI
Hepatology; 2004 Nov; 40(5):1053-61. PubMed ID: 15382154
[TBL] [Abstract][Full Text] [Related]
59. Mutations in the conserved woodchuck hepatitis virus polymerase FLLA and YMDD regions conferring resistance to lamivudine.
Tatti KM; Korba BE; Stang HL; Peek S; Gerin JL; Tennant BC; Schinazi RF
Antiviral Res; 2002 Jul; 55(1):141-50. PubMed ID: 12076758
[TBL] [Abstract][Full Text] [Related]
60. Treatment of chronic hepatitis B: case selection and duration of therapy.
Leung N
J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
